---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-076880"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2022-12-01T23:59:59+00:00"
generated_at: "2026-06-21T10:50:21.858540+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Silo Pharma provides pipeline update, cites $12M cash and zero debt

## Summary
- Cash over $12M, no debt, listed on Nasdaq; pursuing 505(b)(2) pathway for several assets.
- SP-26 (ketamine for fibromyalgia) preparing pre-IND submission; safety evaluation underway.
- SPU-16 (MS) and SPU-21 (RA) under license from University of Maryland; SPU-21 inhibited arthritis in preclinical model.
- SPC-14 (Alzheimer's) showed proof-of-concept in mouse model; SPC-15 (PTSD) under Columbia option.
- Sponsored clinical study with UCSF on psilocybin's anti-inflammatory effects.

## SEC filing metadata
- accession: 0001213900-22-076880
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2022-12-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390022076880/0001213900-22-076880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390022076880/ea169527-8k_silopharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-076880
- JSON: https://secwatch.observer/filing/0001213900-22-076880.json
- Plain text: https://secwatch.observer/filing/0001213900-22-076880.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.